Logo image of OPT

OPTHEA LTD-SPON ADR (OPT) Stock Fundamental Analysis

NASDAQ:OPT - Nasdaq - US68386J2087 - ADR - Currency: USD

5.11  +0.63 (+14.06%)

After market: 4.86 -0.25 (-4.89%)

Fundamental Rating

2

Overall OPT gets a fundamental rating of 2 out of 10. We evaluated OPT against 571 industry peers in the Biotechnology industry. Both the profitability and financial health of OPT have multiple concerns. OPT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

OPT had negative earnings in the past year.
OPT had a negative operating cash flow in the past year.
OPT had negative earnings in each of the past 5 years.
In the past 5 years OPT always reported negative operating cash flow.
OPT Yearly Net Income VS EBIT VS OCF VS FCFOPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

OPT has a worse Return On Assets (-116.66%) than 79.64% of its industry peers.
Industry RankSector Rank
ROA -116.66%
ROE N/A
ROIC N/A
ROA(3y)-138.57%
ROA(5y)-94.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OPT Yearly ROA, ROE, ROICOPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

The Gross Margin of OPT (100.00%) is better than 98.93% of its industry peers.
OPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OPT Yearly Profit, Operating, Gross MarginsOPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

2

2. Health

2.1 Basic Checks

OPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OPT has more shares outstanding
OPT has more shares outstanding than it did 5 years ago.
OPT has a worse debt/assets ratio than last year.
OPT Yearly Shares OutstandingOPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
OPT Yearly Total Debt VS Total AssetsOPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -5.18, we must say that OPT is in the distress zone and has some risk of bankruptcy.
OPT's Altman-Z score of -5.18 is on the low side compared to the rest of the industry. OPT is outperformed by 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.18
ROIC/WACCN/A
WACC8.66%
OPT Yearly LT Debt VS Equity VS FCFOPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

OPT has a Current Ratio of 2.94. This indicates that OPT is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.94, OPT is not doing good in the industry: 66.79% of the companies in the same industry are doing better.
A Quick Ratio of 2.94 indicates that OPT has no problem at all paying its short term obligations.
With a Quick ratio value of 2.94, OPT is not doing good in the industry: 64.64% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.94
Quick Ratio 2.94
OPT Yearly Current Assets VS Current LiabilitesOPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for OPT have decreased strongly by -11.67% in the last year.
The Revenue has grown by 15.04% in the past year. This is quite good.
OPT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.88% yearly.
EPS 1Y (TTM)-11.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.54%
Revenue 1Y (TTM)15.04%
Revenue growth 3Y22.04%
Revenue growth 5Y2.88%
Sales Q2Q%-22.89%

3.2 Future

The Earnings Per Share is expected to grow by 23.01% on average over the next years. This is a very strong growth
Based on estimates for the next years, OPT will show a very strong growth in Revenue. The Revenue will grow by 374.25% on average per year.
EPS Next Y51.79%
EPS Next 2Y32.9%
EPS Next 3Y28.03%
EPS Next 5Y23.01%
Revenue Next Year-21.25%
Revenue Next 2Y1823.11%
Revenue Next 3Y1122.86%
Revenue Next 5Y374.25%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OPT Yearly Revenue VS EstimatesOPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
OPT Yearly EPS VS EstimatesOPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OPT. In the last year negative earnings were reported.
Also next year OPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OPT Price Earnings VS Forward Price EarningsOPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OPT Per share dataOPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

OPT's earnings are expected to grow with 28.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.9%
EPS Next 3Y28.03%

More info and screens

0

5. Dividend

5.1 Amount

OPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OPTHEA LTD-SPON ADR

NASDAQ:OPT (3/3/2025, 8:00:02 PM)

After market: 4.86 -0.25 (-4.89%)

5.11

+0.63 (+14.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26
Earnings (Next)08-28 2025-08-28/amc
Inst Owners40.24%
Inst Owner Change3.27%
Ins Owners1.22%
Ins Owner ChangeN/A
Market Cap786.36M
Analysts76
Price Target6.78 (32.68%)
Short Float %0.29%
Short Ratio16.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)13.16%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)8.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)5%
Revenue NY rev (3m)-25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6306.03
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.42
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-1.05
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0
BVpS-0.49
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -116.66%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-138.57%
ROA(5y)-94.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 26.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.94
Quick Ratio 2.94
Altman-Z -5.18
F-Score3
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)21.93%
Cap/Sales(5y)17.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.54%
EPS Next Y51.79%
EPS Next 2Y32.9%
EPS Next 3Y28.03%
EPS Next 5Y23.01%
Revenue 1Y (TTM)15.04%
Revenue growth 3Y22.04%
Revenue growth 5Y2.88%
Sales Q2Q%-22.89%
Revenue Next Year-21.25%
Revenue Next 2Y1823.11%
Revenue Next 3Y1122.86%
Revenue Next 5Y374.25%
EBIT growth 1Y-27.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.89%
EBIT Next 3Y17.59%
EBIT Next 5Y22.71%
FCF growth 1Y-33.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.5%
OCF growth 3YN/A
OCF growth 5YN/A